ArticleIBRO neuroscience reports2025
Genetic insights into schizophrenia: ERBB4 and GABRB2 polymorphisms in the Lebanese population.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ERBB4 and GABRB2 genes have been given their keen roles in various neurological phenomena, in addition to the involvement of various environmental factors. Aim: To investigate the prevalence of ERBB4 rs839523 C/T and GABRB2 rs1816072 T/C polymorphisms in Lebanese patients with schizophrenia. Materials and methods: A questionnaire-based case-control study recruiting 100 participants of matched characteristics was conducted. A Tetra Primer Amplification Refractory Mutation System Polymerase Reaction (T-ARMS PCR) was performed to evaluate the prevalence of the studied polymorphisms. Results: There were no correlations found between schizophrenia and the ERBB4 rs839523C/T polymorphism (p = 0.096 for genotypes and p = 0.113 for alleles) or the GABRB2 rs1816072 T/C polymorphism (p = 1.00 for genotypes and p = 0.15 for alleles) in the Lebanese population. However, the logistic regression model showed that the mutant homozygous (TT) genotype of the SNP rs839523 in ERBB4 tended to be significant (p = 0.063) with the schizophrenia status. When considering alleles individually, the logistic regression did not reveal any significant associations; however, the C allele of ERBB4 rs839523 showed a trend toward significance. Conclusion: Our findings revealed that the mutant homozygous (TT) genotype of the SNP rs839523 in ERBB4 showed a trend toward significance. These findings suggest a potential role for ERBB4 genetic variation in schizophrenia susceptibility, warranting further investigation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.